Odyssey

The Odyssey study investigated the effects of Alirocumab against placebo on the occurrence of cardiovascular events in patients who have experienced an acute coronary syndrome who were already on statins. Sponsored by Sanofi, this study was a double blinded, randomized, placebo-controlled study and was conducted in 10 sites across Sri Lanka under the supervision of top cardiologists in the country. The project management was done through RemediumOne, a local clinical research organization, under the academic guidance of University of Kelaniya. Sri Lanka managed to contribute 314 patients into the study with a patient retention rate of 93% at the end of the study. The study concluded that among patients who have had a previous acute coronary syndrome, and who were receiving high intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received Alirocumab than those who received placebo.